Clinical and Patient-Reported Outcomes (PROs) in C-POST: A Phase 3 Trial of Adjuvant Cemiplimab Versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC). J of Skin 2025, 9 (6), s688. https://doi.org/10.25251/jy4cvn36.